
Mihai Dorin Vartolomei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2566923/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	0.9	132
2	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	1.2	77
3	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non–muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 389-399.	0.8	72
4	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer. European Urology Oncology, 2018, 1, 403-410.	2.6	66
5	Radiomics in prostate cancer: an up-to-date review. Therapeutic Advances in Urology, 2022, 14, 175628722211090.	0.9	62
6	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 445-452.	0.9	55
7	Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization. International Journal of Molecular Sciences, 2021, 22, 9971.	1.8	55
8	ls neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World Journal of Urology, 2018, 36, 1019-1029.	1.2	54
9	Beyond PSA: The Role of Prostate Health Index (phi). International Journal of Molecular Sciences, 2020, 21, 1184.	1.8	45
10	Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update. Expert Review of Molecular Diagnostics, 2019, 19, 377-387.	1.5	43
11	Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Cleason Score Upgrading in Low-Risk Prostate Cancer Patients. Urologia Internationalis, 2019, 102, 43-50.	0.6	43
12	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	0.8	42
13	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Science OA, 2021, 7, FSO709.	0.9	40
14	Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did WeÂLearn?. Clinical Genitourinary Cancer, 2017, 15, e689-e696.	0.9	39
15	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	1.2	37
16	Comparison Between 64Cu-PSMA-617 PET/CT and 18F-Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence. Clinical Genitourinary Cancer, 2018, 16, 385-391.	0.9	33
17	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. Journal of Cancer, 2018, 9, 4250-4254.	1.2	26
18	Systematic Review: Depression and Anxiety Prevalence in Bladder Cancer Patients. Bladder Cancer, 2018. 4. 319-326.	0.2	26

#	Article	IF	CITATIONS
19	Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 31-37.	3.9	26
20	Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clinical Genitourinary Cancer, 2022, 20, e166-e172.	0.9	26
21	Prognostic value of modified Glasgow Prognostic Score in non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 179.e19-179.e28.	0.8	25
22	Robotic assisted simple prostatectomy. Current Opinion in Urology, 2018, 28, 309-314.	0.9	24
23	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 372-379.	0.8	24
24	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urologia Internationalis, 2018, 101, 7-15.	0.6	22
25	Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. European Urology Focus, 2020, 6, 170-177.	1.6	21
26	The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. Cancers, 2021, 13, 5276.	1.7	21
27	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	0.6	20
28	Prognostic Value of Serum Cholinesterase in Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e1123-e1132.	0.9	19
29	Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. European Urology Focus, 2019, 5, 636-641.	1.6	19
30	Robot-Assisted Vesico-Vaginal Fistula Repair: Our Technique and Review of the Literature. Urologia Internationalis, 2017, 99, 137-142.	0.6	18
31	The impact of moderate wine consumption on the risk of developing prostate cancer. Clinical Epidemiology, 2018, Volume 10, 431-444.	1.5	18
32	High-throughput detection of low abundance sialylated glycoproteins in human serum by TiO2 enrichment and targeted LC-MS/MS analysis: application to a prostate cancer sample set. Analytical and Bioanalytical Chemistry, 2019, 411, 755-763.	1.9	18
33	Bladder Cancer: Depression, Anxiety, and Suicidality Among the Highest-risk Oncology Patients. European Urology Focus, 2020, 6, 1158-1161.	1.6	18
34	Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. Journal of Urology, 2019, 201, 46-55.	0.2	17
35	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multiâ€institutional study. BJU International, 2017, 119, 234-238.	1.3	16
36	Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. European Urology Oncology, 2018, 1, 283-291.	2.6	14

#	Article	IF	CITATIONS
37	Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies. World Journal of Urology, 2020, 39, 1861-1867.	1.2	14
38	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	1.3	14
39	Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. World Journal of Urology, 2019, 37, 2313-2324.	1.2	12
40	Oncological and functional outcomes of postoperative total parenteral nutrition after radical cystectomy in bladder cancer patients: A singleâ€center randomized trial. International Journal of Urology, 2016, 23, 992-999.	0.5	11
41	Oncologic outcomes after minimally invasive surgery for cT1 renal masses. Current Opinion in Urology, 2018, 28, 132-138.	0.9	11
42	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. Frontiers in Oncology, 2021, 11, 651745.	1.3	11
43	Longâ€ŧerm results of a prospective randomized trial assessing the impact of reâ€∎daptation of the dorsolateral peritoneal layer after extended pelvic lymph node dissection and cystectomy. BJU International, 2016, 117, 618-628.	1.3	10
44	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World Journal of Urology, 2016, 34, 1411-1419.	1.2	10
45	Comparison of 10-year overall survival between patients with G1 and G2 grade Ta bladder tumors. Medicine (United States), 2018, 97, e0522.	0.4	10
46	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 123-129.	0.8	10
47	Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms. Aging Male, 2022, 25, 62-66.	0.9	8
48	Fascin-1 and its role as a serological marker in prostate cancer: a prospective case–control study. Future Science OA, 2021, 7, FSO745.	0.9	7
49	Positive Pre-cystectomy Biopsies of the Prostatic Urethra or Bladder Neck Do Not Necessarily Preclude Orthotopic Bladder Substitution. Journal of Urology, 2019, 201, 909-915.	0.2	7
50	Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2016, 68, 381-95.	3.9	7
51	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 528.e7-528.e13.	0.8	6
52	A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer. BJU International, 2022, 130, 306-313.	1.3	6
53	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. World Journal of Urology, 2019, 37, 1049-1059.	1.2	5
54	Easily Available Blood Test Neutrophil-To-Lymphocyte Ratio Predicts Progression in High-Risk Non-Muscle Invasive Bladder Cancer. Romanian Journal of Laboratory Medicine, 2017, 25, 181-189.	0.1	4

#	Article	IF	CITATIONS
55	Outcomes of robot-assisted simple enucleation of renal masses. Medicine (United States), 2017, 96, e6771.	0.4	4
56	Novel Insights into the Molecular Mechanisms of Ischemia/Reperfusion Injury in Kidney Transplantation. Transplantology, 2021, 2, 191-207.	0.3	4
57	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	0.6	4
58	Inflammatory Markers and Thromboembolic Risk in Patients with Non-Muscle-Invasive Bladder Cancer. Journal of Clinical Medicine, 2021, 10, 5270.	1.0	4
59	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urology and Nephrology, 2022, 73, .	1.3	4
60	Fascin is secreted in male's serum: results of a pilot study. Future Science OA, 2018, 4, FSO273.	0.9	3
61	A risk-group classification model in patients withÂbladder cancerÂunder neoadjuvant cisplatin-based combination chemotherapy. Future Oncology, 2021, 17, 3987-3994.	1.1	3
62	The role of neutrophil to lymphocyte ratio in patients with pTa non-muscle invasive bladder cancer. Romanian Journal of Laboratory Medicine, 2020, 28, 29-38.	0.1	2
63	Robot-assisted partial nephrectomy. Current Opinion in Urology, 2018, 28, 123-131.	0.9	1
64	MP38-19 READAPTATION OF THE PERITONEUM FOLLOWING EXTENDED PELVIC LYMPH NODE DISSECTION (PLND) AND CYSTECTOMY HAS BENEFICIAL IMPACT ON BOWEL FUNCTION IN THE LONG TERM WITHOUT COMPROMISING ONCOLOGICAL RADICALITY Journal of Urology, 2016, 195, .	0.2	0
65	The Role of Urologist. , 2018, , 101-112.		0